WO2008111430A1 - γδＴ細胞集団の製造方法 - Google Patents

γδＴ細胞集団の製造方法 Download PDF

Info

Publication number
WO2008111430A1
WO2008111430A1 PCT/JP2008/053855 JP2008053855W WO2008111430A1 WO 2008111430 A1 WO2008111430 A1 WO 2008111430A1 JP 2008053855 W JP2008053855 W JP 2008053855W WO 2008111430 A1 WO2008111430 A1 WO 2008111430A1
Authority
WO
WIPO (PCT)
Prior art keywords
γδt cell
cell population
producing
γδt
producing γδt
Prior art date
Application number
PCT/JP2008/053855
Other languages
English (en)
French (fr)
Inventor
Mitsuko Ideno
Fumiyo Sakai
Tatsuji Enoki
Ikunoshin Kato
Original Assignee
Takara Bio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc. filed Critical Takara Bio Inc.
Priority to US12/450,017 priority Critical patent/US20110158954A1/en
Priority to JP2009503975A priority patent/JPWO2008111430A1/ja
Publication of WO2008111430A1 publication Critical patent/WO2008111430A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　γδＴ細胞を含有する細胞集団を、（ａ）フィブロネクチン、フィブロネクチンフラグメントまたはそれらの混合物、および（ｂ）γδＴ細胞活性化因子の存在下で培養する工程を包含することを特徴とする、γδＴ細胞集団の製造方法。本発明により、γδＴ細胞集団の製造方法が提供される。当該方法により得られるγδＴ細胞は、例えば、免疫療法に好適に使用される。従って、本発明の方法は、医療分野への多大な貢献が期待される。
PCT/JP2008/053855 2007-03-09 2008-03-04 γδＴ細胞集団の製造方法 WO2008111430A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/450,017 US20110158954A1 (en) 2007-03-09 2008-03-04 Method for producing gamma delta t cell population
JP2009503975A JPWO2008111430A1 (ja) 2007-03-09 2008-03-04 γδＴ細胞集団の製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007061039 2007-03-09
JP2007-061039 2007-03-09

Publications (1)

Publication Number Publication Date
WO2008111430A1 true WO2008111430A1 (ja) 2008-09-18

Family

ID=39759373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053855 WO2008111430A1 (ja) 2007-03-09 2008-03-04 γδＴ細胞集団の製造方法

Country Status (4)

Country Link
US (1) US20110158954A1 (ja)
JP (2) JPWO2008111430A1 (ja)
TW (1) TW200844235A (ja)
WO (1) WO2008111430A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014136845A1 (ja) * 2013-03-06 2014-09-12 タカラバイオ株式会社 成熟樹状細胞集団の製造方法
JP2018516586A (ja) * 2015-06-09 2018-06-28 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
WO2018143243A1 (ja) * 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016093350A1 (ja) * 2014-12-11 2016-06-16 国立研究開発法人理化学研究所 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN110699318A (zh) * 2018-07-09 2020-01-17 广西慧宝源健康产业有限公司 T细胞培养基及培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019450A1 (ja) * 2003-08-22 2005-03-03 Takara Bio Inc. 細胞傷害性リンパ球の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2561131B2 (ja) * 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
US5198423A (en) * 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5839663A (en) * 1996-07-23 1998-11-24 United Technologies Corporation Gas turbine exhaust nozzle flap and flap seal apparatus
EP1188825A1 (en) * 2000-09-18 2002-03-20 Universiteit Leiden T cell receptor transfer into a candidate effector cell or a precursor thereof
KR100888915B1 (ko) * 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
ES2397319T3 (es) * 2002-03-25 2013-03-06 Takara Bio Inc. Proceso para producir linfocitos citotóxicos
EP1788078B1 (en) * 2004-07-08 2012-02-08 Medinet., Co. Ltd. Dentritic cell drug containing the dentritic cell, therapeutic method using the dentritic cell and method of culturing gamma delta t cell
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
CA2576571C (en) * 2004-08-19 2013-07-02 University Of Bern Preparation of antigen-presenting human .gamma..delta. t cells and use in immunotherapy
GB0425732D0 (en) * 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
US20090300101A1 (en) * 2008-05-30 2009-12-03 Carl Johan Freer Augmented reality platform and method using letters, numbers, and/or math symbols recognition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019450A1 (ja) * 2003-08-22 2005-03-03 Takara Bio Inc. 細胞傷害性リンパ球の製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERLAZZO V. ET AL.: "In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation", INT. J. IMMUNOPATHOL. PHARMACOL., vol. 19, no. 2, April 2006 (2006-04-01) - June 2006 (2006-06-01), pages 309 - 317 *
KATO Y. ET AL.: "Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate", J. IMMUNOL., vol. 170, no. 7, 1 April 2003 (2003-04-01), pages 3608 - 3613 *
KUNZMANN V. ET AL.: "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma", BLOOD, vol. 96, no. 2, 15 July 2000 (2000-07-15), pages 384 - 392, XP002223785 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014136845A1 (ja) * 2013-03-06 2014-09-12 タカラバイオ株式会社 成熟樹状細胞集団の製造方法
JPWO2014136845A1 (ja) * 2013-03-06 2017-02-16 タカラバイオ株式会社 成熟樹状細胞集団の製造方法
JP2018516586A (ja) * 2015-06-09 2018-06-28 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
WO2018143243A1 (ja) * 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JPWO2018143243A1 (ja) * 2017-02-03 2019-11-21 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JP7224021B2 (ja) 2017-02-03 2023-02-17 国立大学法人神戸大学 人工多能性幹細胞の作製方法

Also Published As

Publication number Publication date
JPWO2008111430A1 (ja) 2010-06-24
US20110158954A1 (en) 2011-06-30
TW200844235A (en) 2008-11-16
JP2013176403A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
MX2008014692A (es) Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
MY161726A (en) Biological methods for preparing adipic acid
WO2007149182A3 (en) Differentiation and enrichment of islet-like cells from human pluripotent stem cells
WO2009126858A3 (en) Materials and methods for improved immunoglycoproteins
MX2012000150A (es) Metodos biologicos para preparar acido adipico.
EA201071058A1 (ru) Получение леналидомида
WO2010001137A3 (en) Microwave torrefaction of biomass
WO2008111430A1 (ja) γδＴ細胞集団の製造方法
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
WO2009137674A3 (en) Treating myelin diseases with optimized cell preparations
WO2010006055A3 (en) Improved gas permeable cell culture device and method of use
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MY163081A (en) Animal cell culturing method
MY181513A (en) Cell culture compositions and methods for polypeptide production
WO2008153179A1 (ja) 脂肪組織由来多系統前駆細胞
WO2006113881A3 (en) Method of using stroma cells from cord blood to expand and engraft nucleated cells from cord blood
WO2009081012A3 (fr) Procedes de production d'acide succinique
MX367078B (es) Cocteles de enzimas preparados a partir de cultivos mezclados.
GEP20135800B (en) Method of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives preparation
WO2010021738A3 (en) Method for producing double-crosslinked collagen
WO2008024769A3 (en) Intensified perfusion production method
WO2010020876A3 (en) Cell culture method to form aggregates
WO2010128024A3 (en) Reversibly immortalized cells as well as methods relating hereto
WO2013022998A3 (en) Production of carboxylates and methane from biomass waste
EP3524672A3 (en) Reprogramming cancer cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721275

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009503975

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721275

Country of ref document: EP

Kind code of ref document: A1